Summary: Interleukin-6 (IL-6) is a neurotrophic cytokine ex pressed in both neurons and glia. The present study shows that cerebral ischemia produced by permanent occlusion of the middle cerebral artery (MCAO) produces a dramatic increase in IL-6 bioactivity in the ischemic hemisphere within 2 hours of MCAO (167 ± 55 IU versus sham: 50 ± 35 IU), with further increases at 8 hours (3,456 ± 1,162 IU) and 24 hours (6,088 ± 1,772 IU). In a separate series of experiments, intracerebroven tricular injection of recombinant IL-6 (3,100 or 31,000 IU) Study of the mechanisms underlying neuronal death due to cerebral ischemia has recently indicated the im portance of immune/inflammatory proteins (cytokines) in this complex pathology. Despite numerous reports of increased expression of various cytokines after experi mentally induced cerebral ischemia, relatively few (e.g., interleukin-l [IL-l]; tumor necrosis factor; nerve growth factor; transforming growth factor-B) have been directly implicated in ischemic brain damage (see Rothwell et aI., 1995; Feuerstein et aI., 1995).
Study of the mechanisms underlying neuronal death due to cerebral ischemia has recently indicated the im portance of immune/inflammatory proteins (cytokines) in this complex pathology. Despite numerous reports of increased expression of various cytokines after experi mentally induced cerebral ischemia, relatively few (e.g., interleukin-l [IL-l] ; tumor necrosis factor; nerve growth factor; transforming growth factor-B) have been directly implicated in ischemic brain damage (see Rothwell et aI., 1995; Feuerstein et aI., 1995) .
IL-6, first identified as B-cell stimulating factor (Kishimoto, 1989) , is also synthesized within neurons and glia, and cerebral expression is increased in a wide variety of CNS disorders, including ischemia (Woodroofe et aI., 1991; Yan et aI., 1992; Taupin et aI., 1993; Wang et aI., 1995) . IL-6 is important to the sur vival of CNS neurons in culture (Hama et aI., 1991) , and plays an important role in peripheral nerve regeneration significantly reduced ischemic brain damage after MCAO (to 52% and 65% of controls, respectively). The large increase in endogenous IL-6 bioactivity in response to ischemia, together with the marked neuroprotection produced by exogenous suggest that this cytokine is an important endogenous inhibitor of neuronal death during cerebral ischemia. Key Words: In terleukin-6-Neuroprotection-Permanent focal cerebral isch emia-MCAO-Rat. (Hirota et aI., 1996) . Furthermore, IL-6 reduces excito toxic-induced neuronal death in hippocampal in vitro (Yamada and Hatanaka, 1994) and striatal cholinergic in vivo (Toulmond et aI., 1992) and prevents learning dis ability and delayed neuronal loss in gerbils after fore brain ischemia (Matsuda et aI., 1996) . However, trans genic mice overexpressing IL-6 in the brain develop se vere neurologic disease, suggesting a complex role for IL-6 in the pathology of CNS disorders (Campbell et aI., 1993) .
Recently, Wang et al (1995) reported that cerebral ischemia, produced by permanent occlusion of the middle cerebral artery (MCAO) causes increased cortical expression of IL-6 mRNA. The present study was un dertaken to clarify the role of IL-6 in permanent cerebral ischemia. We measured brain IL-6 bioactivity after MCAO in the rat, and determined the effect of recom binant human IL-6 (rhIL-6) administration on neuronal death 24 hours after MCAO. Because IL-6 is a potent pyrogen (LeMay et aI., 1990b) and body temperature may influence outcome after MCAO (Ginsberg et aI., 1993; Meden et aI., 1994) , the effect of rhIL-6 adminis tration on the body temperature of ischemic rats was also determined.
MATERIALS AND METHODS
All experiments were performed on male, Sprague-Dawley rats (Charles River, United Kingdom), weighing 230 g to 270 g. Animals were housed at an ambient temperature of 21°C with a 12-hour light/dark cycle (lights on 7 AM) and allowed free access to food and water.
Cerebral ischemia was induced under halothane anesthesia by permanent unilateral occlusion of the left middle cerebral artery using an adaptation (Bederson et aI., 1986 ) of the method originally described by Tamura et al (1981) (see Loddick and Rothwell, 1996 , for detailed description). Sham-operated ani mals were subjected to the same procedure, except the artery was not occluded.
To determine the effect of MCAO on brain IL-6 bioactivity, animals were subjected to MCAO or sham surgery, killed by decapitation 2 hours (MCAO: n = 4; sham: n = 4), 8 hours (MCAO: n = 4; sham: n = 3), or 24 hours (MCAO: n = 4; sham: n = 4) later and the brains immediately removed and frozen. Each hemisphere was homogenized in I mL of phos phate-buffered saline, then spun at 14,000g on a bench-top microfuge (Eppendorf 5402; VWR, Brisbane, CA, U. S.A.).
The supernatant was retained and assessed for IL-6 bioactivity using the 7TDI cell line, as previously described (Turnbull and Rivier, 1996) . Specificity of this assay for IL-6 was shown by In a second series of experiments, the effects of injection of rhIL-6 (Sandoz, USA, biological activity = 6.2 x 107 IV/mg) on lesion size and body temperature (T b) after MCAO were detennined. Animals were equipped with intracerebroventricu lar guide cannulae to permit intracerebral injections and intra peritoneal radio transmitters (Data Sciences, USA) to allow the recording of T b by remote radio telemetry (as described in Loddick and Rothwell, 1996) . The recording of T b was com menced 6 days later at 8 AM. Tb was recorded continuously for 24 hours before MCAO/sham surgery to obtain a baseline pro file for each animal. Conscious rats (hand-held) were injected intracerebroventricularly with either saline (4 IJ-L) or rhIL-6 (50 ng = 3,100 IV, or 500 ng = 31,000 IV). Because of the short half-life of rhIL-6 in the brain (42 minutes, Banks et aI., 1994) two injections of rhIL-6 were administered 30 minutes before and 15 minutes after MCAO. After injection, Tb measurement continued. Twenty-four hours after surgery, animals were killed and the brain removed. Delineation of the lesion was performed on fresh 500-f,Lm coronal brain sections incubated in 2% triphenyl tetrazolium chloride (TTC; Sigma Chemical Co., United Kingdom) using an indirect approach, thus "correct ing" for any swelling (for detailed description, see Loddick and Rothwell, 1996) . Lesion volume was calculated for each brain by integration of the areas of infarct in each section. All analy ses were performed "blind."
All data are expressed as mean ± SD. Statistical differences in IL-6 bioactivity were analyzed using the paired Students t-test by comparing 10gl O transformed values (LeMay et aI., 1990a) in the two hemispheres. Differences between lesion volume were analyzed using one-factor analysis of variance (ANOVA), followed by Tukey's post-hoc test. Temperature data were analyzed by multivariate ANOV A with repeated measures.
RESULTS
MCAO produced a rapid, dramatic and sustained in crease in IL-6 bioactivity in the ischemic hemisphere (Table I) . This increase was apparent by 2 hours (167 ± 55 IUJhemisphere; versus 10 ± 8 IU in contralateral hemisphere), more marked by 8 hours (3456 ± 1162 IUJhemisphere), and further increased at 24 hours (6096 ± 1772 IUJhemisphere). Much smaller (23-fold to 25-fold less) increases in IL-6 activity were also apparent in both the contralateral hemisphere of rats subjected to MCAO and in the ipsilateral hemisphere of sham operated animals.
Intracerebroventricular injection of rhIL-6 dramati cally reduced ischemic brain damage measured 24 hours after MCAO (Fig. 1) . This was evident as a significant reduction (versus vehicle treated) in total, (50 ng: 48 ± 4%; 500 ng: 35 ± 6%), cortical (50 ng: 45 ± 5%; 500 ng: 34 ± 6%), and striatal lesion volume (50 ng: 62 ± 6%; 500 ng: 37 ± 5%) compared to animals injected with saline.
The effect of rhIL-6 on T b of rats subjected to MCAO is presented in Table 2 as the change in T b after ischemia relative to the values obtained during the previous days recordings, thus avoiding the influence of circadian variation. Before surgery, T b was similar in all groups (saline: 37.4 ± 0.1 °C; 50 ng rhIL-6: 37.4 ± 0.1 °C; 500 ng rhIL-6: 37.4 ± 0.1°C). A transient hypothermia «1°C) was observed in all groups as animals recovered from anesthesia. However, within 4 hours, the Tb of saline injected rats returned to values similar to those recorded on the previous day, and remained constant thereafter. rhIL-6 produced a dose-dependent increase in T b that was statistically significant only at the 500-ng dose and was apparent by 4 hours, peaked at 5 hours, and returned to values similar to saline-injected rats by 10 hours.
DISCUSSION
This study shows that permanent focal cerebral isch emia produces a dramatic increase in brain IL-6 activity, and exogenous lL-6 reduces ischemic damage after MCAO in the rat. The present study does not identify the cellular or even tissue source of IL-6. The rapid induc tion of IL-6 by ischemia suggests production by consti tutive brain cells. Infiltrating inflammatory cells are not • Saline iii +1Smin) SoOng rhlL-S (-30, +15min) FIG. 1. Lesion volume measured 24th after middle cerebral ar tery occlusion (MCAO) in rats injected intracerebroventricularly with either saline (4 �L, n = 9), 50 ng recombinant human inter leukin-6 (rhIL-6) (n = 8) or 500 ng rhlL-6 (n = 8) 30 minutes before and 15 minutes after MCAO. Values denote the mean, and error bars indicate SD. ***P < .001 versus saline-treated group; **P < 0.01 versus saline-treated group.
detected in the brain until 12 hours after MCAO (Clarke et aI., 1993) . Thus, although these cells could contribute to IL-6 bioactivity detected at 24 hours, they cannot ac count for the profound increase in bioactivity 8 hours after MCAO. Although neurons and neurovasculature are capable of producing IL-6 (SchObitz et a!., 1992; Rott et aI., 1993), astrocytes and/or microglia are the likely source(s) after brain injury/ischemia (Woodroofe et aI., 1991; Maeda et aI., 1994) . We also observed a modest increase in IL-6 bioactivity after sham surgery, and in the contralateral hemisphere after MCAO, consistent with a previous observation of increased IL-6 expression in both hemispheres after mechanical brain injury (Taupin et aI., 1993) . Because it is unlikely that the IL-6 detected in the contralateral hemisphere is derived from the isch emic hemisphere due to the different time-course of IL-6 expression, this observation suggests that the contralat eral hemisphere synthesizes IL-6. The reason for this synthesis is unknown, but it may be due to physical rhIL-6 (500 ng, 31000 IV) -0.2 ± 0.3 +0.4 ± 0.8 +1.0 ± 0.6 +0.8 ±0.6 +0.7 ± 0.6 -0.1 ± 0.6 Data are presented as change in Tc (mean ± SD) from values re corded over 24 hours before MCAO, in animals injected icv with either saline (4 fLL, n = 9), 50 ng rhIL-6 (n = 8) or 500 ng rhIL-6 (n = 8) 30 minutes before and IS minutes after MCAO.
.I Cereb Blood Flow Metab, Vol. 18, No.2. 1998 deformation of tissue resulting from swelling of the isch emic hemisphere .
To determine if IL-6 present in ischemic brain could influence neuronal survival, we investigated the effect of administration of rhIL-6 on ischemic damage after MCAO. Based on the amount of endogenous IL-6 bio activity found in ischemic hemispheres (3,260 IU to 5,868 IU), two doses of rhIL-6 were tested, equivalent to 3,100 IU and 31,000 IU, respectively. Both doses caused a dramatic reduction in ischemic damage throughout both the cortex and striatum. The higher dose was less effective at reducing ischemic damage, which may relate to the dramatic increase in Tb, which may have exacer bated neuronal death (Ginsberg et aI., 1993; Meden et aI., 1994) . Regardless of effects on Tb, exogenous rhIL-6 was clearly neuroprotective at doses (3,100 IU to 31,000 IU) similar to the amount of endogenous IL-6 bioactivity found in ischemic hemispheres (3, 260 IU to 5, 868 IU) . Although the effects of neutralization of endogenous IL-6 were not tested here because of lack of suitable reagents, that administration of physiologically relevant doses of IL-6 provides protection suggests that cerebral IL-6 generated during ischemia may be an important endogenous neuroprotective factor.
The present study did not investigate the mechanism by which IL-6 influences neuronal survival after isch emia. A modification of Tb is unlikely to account for the observed effects because the fever produced by IL-6 would be expected to exacerbate rather than inhibit neu ronal death (Ginsberg et a!., 1993; Meden et a!., 1994 ). An effect of rhIL-6 on neuronal viability secondary to changes in physiologic variables such as blood pressure and blood flow is possible. However, IL-6 protects hip pocampal neurons in vivo without affecting hippocampal blood flow (Matsuda et aI., 1996) and protects against excitotoxicity in vitro (Yamada and Hatanaka, 1994) suggesting a direct action of IL-6 on neuronal viability. In the rat, mRNA encoding IL-6 and both its receptor subunits (lL-6 receptor a-chain and gp130) share similar distributions in the brain (Schobitz et aI., 1992; SchObitz et aI., 1993; Watanabe et aI., 1996) , and are all present in the cortex and striatum, areas where rhIL-6 reduced isch emic damage after MCAO. IL-6 may produce neuropro tection by an action directly on or secondary to release of intermediates by glial cells because IL-6 receptors are present in both cell types (Schobitz et aI., 1992; Watan abe et aI., 1996) . Furthermore, that rhIL-6 protects against excitoxicity both in vivo and in vitro suggests that its neuroprotective effects during ischemic brain damage may be downstream of excitatory amino acid receptor activation.
The effects of IL-6 on neuronal death after MCAO are in marked contrast to those of a related cytokine, IL-l. We and others have provided convincing evidence that IL-l exacerbates ischemic brain damage and is an en-dogenous neurotoxic factor in cerebral ischemia (Relton and Rothwell, 1992; Yamasaki et aI., 1995; Loddick and Rothwell, 1996) and excitatory amino acid-induced ex citotoxicity (ReIton and Rothwell, 1992) . Although IL-6 and IL-l share many common actions (e.g., fever, acute phase protein synthesis, activation of the pituitary adrenal axis), IL-6 can inhibit IL-l synthesis (Schindler et aI., 1990 ) and stimulates production of the endogenous receptor antagonist (Tilg et aI., 1994) , actions that may also contribute to its neuroprotective effects.
In conclusion, we have shown for the first time that cerebral administration of rhIL-6 produces a profound reduction in neuronal death due to permanent cerebral ischemia in the rat. Because our work also shows that the concentration of endogenous IL-6 in ischemic brain tis sue is markedly increased, we propose that IL-6 is an important endogenous neuroprotective factor.
